Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Seeking Alpha
Company Participants Mark Goldsmith - CEO, President & Chairman Conference Call Participants Marc Frahm - TD Cowen, Research Division Presentation Marc Frahm TD Cowen, Research Division So welcome back to the 46th Annual TD Cowen Healthcare Conference. I'm Marc Frahm, from the biotech team here at TD Cowen. Very happy to have with us Mark Goldsmith, President and CEO of Revolution Medicines for the next session, where we're going to talk a lot about different ways to target RAS. So maybe to start off with, Mark, you kind of just level set people, high-level overview and kind of what you see as the key value creation events for investors over the next 12, 18 months or so? Question-and-Answer Session Mark Goldsmith CEO, President & Chairman Well, thanks for having me here today. It's a pleasure to talk to you. Well, I think the most standout event of the year is going to be the readout of the RASolute 302 trial, which is our trial in previously treated pancreati
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines (RVMD) is now covered by UBS Group AG. They set a "buy" rating and a $145.00 price target on the stock.MarketBeat
- Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform Rating – Here's Why [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines (RVMD) had its price target raised by Wells Fargo & Company from $100.00 to $144.00. They now have an "overweight" rating on the stock.MarketBeat
- Revolution Medicines (RVMD) had its price target raised by Piper Sandler from $75.00 to $120.00. They now have an "overweight" rating on the stock.MarketBeat
RVMD
Earnings
- 2/25/26 - Miss
RVMD
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- RVMD's page on the SEC website